AnHorn Medicines Gains FDA IND Clearance and Taiwan CDE Index Case for AH-008

AnHorn Medicines announced that its lead neuroprotective candidate AH-008 has achieved two regulatory milestones: Investigational New Drug clearance from the U.S. Food and Drug Administration (FDA) and Index Case designation from the Taiwan Center for Drug Evaluation in a press release.

The FDA clearance authorizes AH-008 to begin human clinical trials after review of its preclinical pharmacology, toxicology, and manufacturing data. The Taiwan CDE Index Case designation identifies AH-008 as a reference program for new drug development in its category and is expected to support efficient regulatory interaction.

AH-008 is being developed to prevent chemotherapy-induced peripheral neuropathy, a common side effect of cancer treatment that can cause nerve damage and limit chemotherapy dosing. Preclinical studies showed that AH-008 preserved nerve integrity while maintaining chemotherapy effectiveness.

AnHorn advanced AH-008 from preclinical stage to FDA clearance within 12 months, reflecting its integrated development capabilities. The company uses its AIMCADD AI platform to design small molecules and protein degraders for oncology and supportive care applications.